Post on 04-Feb-2018
Ekso Bionics
Company Overview
June 2014
Proprietary | 2
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements may include, without limitation, statements regarding (i) the plans and objectives of management for future operations, including plans or objectives relating to the design, development and commercialization of human exoskeletons, (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items, (iii) the Company's future financial performance and (iv) the assumptions underlying or relating to any statement described in points (i), (ii) or (iii) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain adequate financing, the significant length of time and resources associated with the development of our products and related insufficient cash flows and resulting illiquidity, the Company's inability to expand the Company's business, significant government regulation of medical devices and the healthcare industry, lack of product diversification, volatility in the price of the Company's raw materials, existing or increased competition, results of arbitration and litigation, stock volatility and illiquidity, and the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC, including, the Company's Current Report on Form 8-K filed on March 31, 2014. The Company does not undertake to update these forward-looking statements.
FORWARD LOOKING STATEMENTS
Proprietary | 3
Lisa Hughes
FIRST, SOME INTRODUCTIONS
Jason Gieser
Proprietary | 4
INTRODUCTION TO EKSO BIONICS
Ekso Bionics designs and develops wearable robotic
exoskeletons to augment human strength, endurance,
and mobility
• We are in the midst of one of the greatest technological
revolutions in history
• We are committed to applying the latest technology and
engineering to help people rethink current physical limitations and
achieve the remarkable.
• We are executing a synergistic dual business strategy
o Technology and IP developer through leading R&D and
engineering capability;
o Designer, manufacturer and distributor of advanced
wearable robotic exoskeletons
EKSO LABS
EKSO
LABS
Expands
Exoskeleton
Functionality Lockheed
Martin
• HULC
• Mantis
DARPA
An
Original
Idea With
The Future
In Mind
National
Science
Foundation
EKSO™
HULC MANTIS TALOS
US Special
Operations
Command
• TALOS
Continually
Integrating
Emerging
Technologies
We Developed Our Own Exoskeleton Laboratory
EXOHIKER
Healthcare
Products
“EKSO”
“GT”
EKSO GT™
Proprietary | 5
Proprietary and Confidential | 6
MULTIPLE LARGE MARKET APPLICATIONS
Current Market Additional Market Applications
Healthcare Rehab Healthcare Home Military Industrial Consumer
Medical Military Industrial Consumer
Applications
• Spinal Cord Injury
(“SCI”)
• Stroke
• Traumatic Brain Injury
• Early Mobilization
• Cerebral Palsy
• At Home Rehab
• Gait Training
• Wellness
• Added mobility
option
• Ground Soldiers
• Depots
Manufacturing
• Logistics
• Construction
• First Response
• Manufacturing
• Moving
• Elderly
• Outdoor Sports
• Extreme Athletics
Customers
• Neuro-Rehab Centers
US and Europe
• Distributors
• Individuals
• At Home HC
Providers
• Lockheed Martin
• DARPA
• US SOCOM
• Lockheed Martin
• Retail
TALOS - NEXT GENERATION EXOSKELETONS
US Special Operations Command (USSOCOM)
o TALOS – R&D project led by Admiral McRaven to develop the Iron Man suit
o Ekso Bionics first company globally to be awarded a contract under this program,
direct with USSOCOM
o Developing technologies that will apply to many able bodied applications
o Ekso Bionics-developed IP to remain with Ekso Bionics
Proprietary | 7
Healthcare Rehabilitation Market
"The Ekso suit has given me a chance to do something that I
never thought I would ever do again. I can walk and look
people in the eye. I can hug people.” Tamara Mena, Ekso
Ambassador
Proprietary | 8
Proprietary | 9
• 800,000 Stroke Cases Each Year (2)
• Most will Have Some Level of Hemiplegia
• Ekso can address ~25% of stroke survivors (3)
HEALTHCARE REHAB MARKET OVERVIEW
STROKE SPINAL CORD INJURY
•14,000 Spinal Cord Injuries Each Year in US (4)
• Potential Ekso Patients Include:
•All complete and incomplete paraplegics
•All incomplete tetraplegics
• Ekso can serve as a tool to prevent re-hospitalization
(2) (3) (Source) The Christopher and Dana Reeves Foundation
(Source) Wintergreen Research (1)
(4)
ROBOTIC REHAB TO GROW 181% PER YEAR (1) 5.6 M IN US LIVE WITH PARALYSIS
51 64 112 256
663
1,240
1,882
0
500
1,000
1,500
2,000
2014 2015 2016 2017 2018 2019 2020
In U
S$000,0
00
Rehab Robot Market Forecast, Worldwide
Proprietary | 10
GROWING WORLDWIDE REHAB PRESENCE
NORTH AMERICA EUROPE
60 centers as of Q1, 2014 in US, Europe, Canada, Mexico,
and South Africa
Proprietary | 11
HOW THIS EXPANSION WILL CONTINUE
• Clinical Efficacy – an expanding group of KOLs are
sharing preliminary data
• Beating expectations for exoskeletons
• PLEASE – Check our references!
• Reimbursement – believe it or not – is not important now,
will be when we eventually go into homes.
• Adoption – Growing number of multi-Ekso customers.
• Return on Investment – Multiple ways our customers are
seeing Ekso pay for itself
Proprietary | 12
PROSPECTIVE BENEFITS AND ROI
Benefits Facts, Figures and Anecdotes
Attracts additional
patients
“[The Ekso] attracted 12 new SCI inpatients
to our facility”
Reduces length of Stay Patients are 86% more likely to go home if
able to walk
Increase bed turnover
Mitigates providers’ exposure to capitation
of reimbursement not solely tied to length of
stay
Reduces readmissions “Few stroke patients survive for 5 years
without a hospital readmission”
Reduces medical costs
“reported reduction in habitual
musculoskeletal pain, and lessening of
lower extremity muscle spasms.”
Prevents injuries to
physical therapists
Patient repositioning is a major cause of
work-related injuries and missed time for
PTs.
Leads to additional rehab
hours
“It was phenomenal…walking on my own
two feet, walking naturally”
Prospective Benefits Facts, Figures and Anecdotes
Improve overall health Improves both psychological and
physical health
Reduce hospital readmissions
Prevents UTIs, pneumonia, pressure
ulcers and many other complications
(~$10K annually)
Require fewer checkups Upholds better overall health saving
money on checkups (~$3K annually)
Save money on prescriptions “I no longer need spasticity
medications” (~$4K annually)
Fewer rehab sessions “I will be able to do rehab in my own
home” (~$4K annually)
Less home remodeling Individuals will eventually have much
more mobility around their homes
Reduce Social Costs 90% of SCI patients do not return to
work
REHAB MARKET: PROVIDERS
Cost Savings and Revenue Generation
HOME MARKET: PAYERS AND PATIENTS
Cost Savings and Health Improvement
Proprietary | 13
30 Unique U.S. Patents
o Status
• 7 issued
• 11 in prosecution
• 12 provisional
o Ownership
• 6 exclusively licensed from UCB
• 7 co-owned with UCB
• 17 held by Ekso Bionics
95 International Applications
IP – ACROSS ALL OF OUR MARKETS
Military Medical Commercial
Industrial
We have aggressively pursued IP for Medical, Military, and Commercial applications
Subject matter ranges from novel customer features to advanced control systems
By making full use of the international patent treaties, we have broad coverage overseas
RUC006
RUC006C
RUC003
BBI006
BBI004
EKS010
EKSO07
RUC007
BBI005
BBI005CIP
BBI009
BBI010
EKS002
BB1004C
EKSO04
RUC004
RUC005
BBI003
BBI002
BBI007
BBI008
EKSO03
EKSO05
EKSO06
EKSO08
EKSO09
EKSO12
EKSO13
EKSO14
EKSO15
Let’s Walk
Proprietary | 14
Proprietary | 15
Complete PP and APO to enable business plan through mid-2015.
Hire Senior Sales and Marketing Executives
• Tom Looby, Chief Marketing Officer
• Glenn Davis, VP North America Sales
Secure Two New Ekso Lab Projects
TALOS Secured
Grow IP through additional non-dilutive funding
Expand Licensing Partnerships
Cross over 10 million steps for Ekso medical devices
2014-2015 MILESTONES
Proprietary | 16
• As of March 2014, ~$80 million has been invested in Ekso’s Technology
• Of that, ~$35 million has been non-dilutive:
o ~$27 million has been in the form of grants from DARPA, NSF, NIST and others
o ~$7 million as non-recurring engineering services from Lockheed and the US Government
o $1 million in license payments
• ~$45 million in equity invested to date
• Our APO
o First closing January 15, 2014; final closing February 6
o 30.3 million units - $1.00 share plus a $2.00 five-year warrant
o After repayment of debt and fees, netted ~$19 million.
o 78.4 million actual shares outstanding
o 129.5 million fully diluted
INSTITUTIONAL INVESTORS RECENTLY ENTERING
20.3%
19.5%
16.9%
43.3%
Summary Cap Table, Post APO
Founders andEmployees
Institutions
ChickasawNation/Lockheed
Individuals/Other
Proprietary | 17
Thank You
“Walking in the Ekso means that I was able to keep a promise
to my family that I would walk again after my accident.”
Chris Tagatac, Ekso Ambassador